Literature DB >> 2014541

The hemodynamic effects of Cremophor-EL.

V D Bowers1, S Locker, S Ames, W Jennings, R J Corry.   

Abstract

A problem associated with parenteral cyclosporine has been the increased incidence of renal toxicity. Cremophor-EL, the vehicle for parenteral cyclosporine has been associated with massive histamine release and anaphylaxis in certain animal models. We investigated the effects of Cremophor-EL on the cardiac output (CO); mean arterial pressure (MAP); and hepatic, renal and pancreatic blood flow in the anesthesized canine model. Doppler flow probes were utilized to calculate individual organ blood flow. Profound adverse affects were noted on the CO, MAP, and hepatic blood flow. There were negative trends noted in the renal and splenic arterial flow that did not reach statistical significance. It was noted that the changes in organ blood flow were partially independent on MAP and the total dose of Cremophor-EL. We therefore conclude that it is prudent to consider the possible adverse hemodynamic role of Cremophor-EL in canine allograft dysfunction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014541     DOI: 10.1097/00007890-199104000-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain.

Authors:  H Sanchez; J Zoll; X Bigard; V Veksler; B Mettauer; E Lampert; J Lonsdorfer; R Ventura-Clapier
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

3.  Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.

Authors:  Zheng Huang; Qun Chen; David Luck; Jill Beckers; Brian C Wilson; Nadira Trncic; Susan M Larue; Dominique Blanc; Fred W Hetzel
Journal:  Lasers Surg Med       Date:  2005-06       Impact factor: 4.025

4.  Commercial taxane formulations induce stomatocytosis and increase blood viscosity.

Authors:  M Mark; R Walter; D O Meredith; W H Reinhart
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice.

Authors:  José Hureaux; Frédéric Lagarce; Frédéric Gagnadoux; Marie-Christine Rousselet; Valérie Moal; Thierry Urban; Jean-Pierre Benoit
Journal:  Pharm Res       Date:  2010-03       Impact factor: 4.200

6.  Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Authors:  Shaoman Yin; Stefan Kaluz; Narra S Devi; Adnan A Jabbar; Rita G de Noronha; Jiyoung Mun; Zhaobin Zhang; Purushotham R Boreddy; Wei Wang; Zhibo Wang; Thomas Abbruscato; Zhengjia Chen; Jeffrey J Olson; Ruiwen Zhang; Mark M Goodman; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2012-08-24       Impact factor: 12.531

7.  Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats.

Authors:  M J Lee; R M Straubinger; W J Jusko
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

8.  KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Authors:  Wei Wang; Lin Ao; Elizabeth R Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G Van Meir; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.